- Home
- ACET vs RENB Comparison
ACET vs RENB Comparison
Compare ACET & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- RENB
- Stock Information
- Founded
- ACET 1947
- RENB 2011
- Country
- ACET United States
- RENB United States
- Employees
- ACET N/A
- RENB N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- ACET Health Care
- RENB Health Care
- Exchange
- ACET Nasdaq
- RENB Nasdaq
- Market Cap
- ACET 64.9M
- RENB 62.0M
- IPO Year
- ACET N/A
- RENB N/A
- Fundamental
- Price
- ACET $0.61
- RENB $0.29
- Analyst Decision
- ACET Buy
- RENB
- Analyst Count
- ACET 6
- RENB 0
- Target Price
- ACET $6.00
- RENB N/A
- AVG Volume (30 Days)
- ACET 398.4K
- RENB 4.2M
- Earning Date
- ACET 08-12-2025
- RENB 05-15-2025
- Dividend Yield
- ACET N/A
- RENB N/A
- EPS Growth
- ACET N/A
- RENB N/A
- EPS
- ACET N/A
- RENB N/A
- Revenue
- ACET N/A
- RENB N/A
- Revenue This Year
- ACET N/A
- RENB N/A
- Revenue Next Year
- ACET N/A
- RENB N/A
- P/E Ratio
- ACET N/A
- RENB N/A
- Revenue Growth
- ACET N/A
- RENB N/A
- 52 Week Low
- ACET $0.45
- RENB $0.27
- 52 Week High
- ACET $1.70
- RENB $2.10
- Technical
- Relative Strength Index (RSI)
- ACET 38.76
- RENB 40.92
- Support Level
- ACET $0.61
- RENB $0.33
- Resistance Level
- ACET $0.69
- RENB $0.37
- Average True Range (ATR)
- ACET 0.04
- RENB 0.04
- MACD
- ACET -0.01
- RENB -0.01
- Stochastic Oscillator
- ACET 12.80
- RENB 14.96
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.